Verona Pharma (VRNA) Price & Analysis

Compare

857 Followers

VRNA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$31.09 - $106.93

Previous CloseN/A

Volume658.49K

Average Volume (3M)1.47M

Market Cap

$9.19B

Enterprise Value$8.40B

Total Cash (Recent Filing)$438.02M

Total Debt (Recent Filing)$244.37M

Price to Earnings (P/E)―

Beta1.60

Next Earnings

Nov 11, 2025

EPS Estimate

0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding86,495,865

10 Day Avg. Volume1,582,868

30 Day Avg. Volume1,469,715

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.91

Enterprise Value/Revenue37.91

Enterprise Value/Gross Profit39.84

Enterprise Value/Ebitda-229.61

Forecast

1Y Price Target

$105.83

Price Target Upside-1.01% Downside

Rating ConsensusHold

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Product InnovationOhtuvayre, a first-in-class selective dual inhibitor of PDE3 and PDE4, is the first novel inhaled mechanism for the treatment of COPD in more than 20 years, offering bronchodilator and non-steroidal anti-inflammatory effects.

Revenue GrowthSince its approval and commercial launch, Ohtuvayre has established strong revenue growth, showing a fast adoption among physicians and patients.

Bears Say

Financial PerformanceIncreased costs have been modeled, resulting in a reduction in net income for 2025.

Market PerceptionIn the wake of the deal announcement, the rating was downgraded to Neutral from the prior Buy.

Verona Pharma News

Merck completes acquisition of Verona Pharma

Merck (MRK) announced the completion of the Verona Pharma (VRNA) acquisition. Verona Pharma is now a wholly-owned subsidiary...

7d ago

MRK

VRNA

Verona gets England, Wales high court approval for acquisition by Merck

Verona Pharma (VRNA), which entered into a definitive agreement on July 8 relating to its proposed acquisition by...

8d ago

MRK

VRNA

Verona Pharma shareholders approve proposed acquisition by Merck

Verona Pharma (VRNA) announced its shareholders have approved the proposal for Merck (MRK) to acquire the company for...

20d ago

MRK

VRNA

Verona Pharma Completes Acquisition and Delisting Process

Verona Pharma ( ($VRNA) ) has shared an announcement. On October 6, 2025, the High Court of Justice...

7d ago

VRNA

Verona Pharma Shareholders Approve Merck Acquisition

Verona Pharma ( ($VRNA) ) has provided an update. On September 24, 2025, Verona Pharma‘s shareholders approved the...

19d ago

VRNA

Verona Pharma Extends Severance Benefits Amid Merck Deal

Verona Pharma ( ($VRNA) ) has issued an announcement. On September 5, 2025, Verona Pharma‘s Board of Directors...

1M ago

VRNA

Verona Pharma’s New COPD Study: What Investors Need to Know

Verona Pharma (UK) (($GB:VRP)), Verona Pharma (($VRNA)) announced an update on their ongoing clinical study. Verona Pharma is...

2M ago

VRNA

Verona Pharma’s New COPD Study: A Potential Game-Changer?

Verona Pharma (UK) (($GB:VRP)), Verona Pharma (($VRNA)) announced an update on their ongoing clinical study. Verona Pharma has...

2M ago

VRNA

Verona Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

3M ago

VRNA

Verona Pharma downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from...

3M ago

VRNA

Verona Pharma downgraded to Hold from Buy at Truist

Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100,...

3M ago

MRK

VRNA

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK)...

3M ago

VRNA

Verona Pharma downgraded to Neutral from Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

3M ago

VRNA

Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal

Verona Pharma stock soared on Wednesday after the Ohtuvayre maker announced a $10 billion deal with Merck. ...

3M ago

MRK

VRNA

VRNA FAQ

What was Verona Pharma’s price range in the past 12 months?

Verona Pharma lowest stock price was $31.09 and its highest was $106.93 in the past 12 months.

What is Verona Pharma’s market cap?

Verona Pharma’s market cap is $9.19B.

When is Verona Pharma’s upcoming earnings report date?

Verona Pharma’s upcoming earnings report date is Nov 11, 2025 which is in 28 days.

How were Verona Pharma’s earnings last quarter?

Verona Pharma released its earnings results on Jul 31, 2025. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of $0.029 by -$0.034.

Is Verona Pharma overvalued?

According to Wall Street analysts Verona Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Verona Pharma pay dividends?

Verona Pharma does not currently pay dividends.

What is Verona Pharma’s EPS estimate?

Verona Pharma’s EPS estimate is 0.14.

How many shares outstanding does Verona Pharma have?

Verona Pharma has 86,495,865 shares outstanding.

What happened to Verona Pharma’s price movement after its last earnings report?

Verona Pharma reported an EPS of -$0.005 in its last earnings report, missing expectations of $0.029. Following the earnings report the stock price went down -0.048%.

Which hedge fund is a major shareholder of Verona Pharma?

Currently, no hedge funds are holding shares in VRNA

Verona Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-36.38%

Trailing 12-Months

Asset Growth

31.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Verona Pharma

Verona Pharma (VRNA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases. The company is primarily involved in the research and development of novel compounds that target unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Verona Pharma's lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to improve lung function and reduce inflammation.

Verona Pharma (VRNA) Earnings & Revenues

Historic Earnings Reports

VRNA Stock 12 Month Forecast

Average Price Target

$105.83

▼(-1.01% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","61":"$61","108":"$108","37.5":"$37.5","84.5":"$84.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$107.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,37.5,61,84.5,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.75076923076924,93.02153846153847,94.2923076923077,95.56307692307692,96.83384615384615,98.10461538461539,99.37538461538462,100.64615384615385,101.91692307692308,103.18769230769232,104.45846153846153,105.72923076923077,{"y":107,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.66076923076923,92.84153846153846,94.02230769230769,95.20307692307692,96.38384615384615,97.5646153846154,98.74538461538461,99.92615384615385,101.10692307692308,102.28769230769231,103.46846153846154,104.64923076923077,{"y":105.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.21230769230769,91.94461538461539,92.67692307692307,93.40923076923077,94.14153846153846,94.87384615384616,95.60615384615384,96.33846153846154,97.07076923076923,97.80307692307693,98.53538461538461,99.2676923076923,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >